7-溴-4-甲基-2H-苯并[B][1,4]噁嗪-3(4H)-酮 | 1260778-66-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶嗪类
• 中文名称: 7-溴-4-甲基-2H-苯并[B][1,4]噁嗪-3(4H)-酮
• 英文名称: 7-bromo-4-methyl-2H-benzo[b][1,4]oxazin-3(4H)-one
• 英文别名: 7-Bromo-4-methyl-2H-1,4-benzoxazin-3-one；7-bromo-4-methyl-1,4-benzoxazin-3-one
• CAS: 1260778-66-2
• 化学式: C₉H₈BrNO₂
• 分子量: 242.072
• InChiKey: PAIXLUJFHMKEMR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险性防范说明：
  P264,P280,P302+P352,P305+P351+P338,P332+P313,P337+P313,P362
• 危险性描述：
  H315,H319

上下游信息

• 上游原料

  中文名称	英文名称	CAS号	化学式	分子量
  7-溴-2H-苯并[b][1,4]噁嗪-3(4H)-酮	7-bromo-2H-benzo[b][1,4]oxazin-3(4H)-one	321436-06-0	C8H6BrNO2	228.045

• 下游产品

  中文名称	英文名称	CAS号	化学式	分子量
  ——	4-methyl-7-(pyridin-3-yl)-2H-benzo[b][1,4]oxazin-3(4H)-one	1194455-04-3	C14H12N2O2	240.261

反应信息

• 作为反应物：
  描述：

  7-溴-4-甲基-2H-苯并[B][1,4]噁嗪-3(4H)-酮 在 四(三苯基膦)钯 、 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 potassium acetate 、 sodium carbonate 作用下， 以 1,4-二氧六环 、 乙醇 、 水 为溶剂， 反应 32.0h， 生成 7-(5-((1-(ethylsulfonyl)azetidin-3-yl)oxy)pyridin-3-yl)-4-methyl-2H-benzo[b][1,4]oxazin-3(4H)-one
  参考文献：
  名称：

  吡啶多环类化合物抑制剂、及其制备方法和应用

  摘要：

  本发明涉及吡啶多环类化合物抑制剂、及其制备方法和应用。特别地，本发明涉及通式(I)所示的化合物、其制备方法及含有该化合物的药物组合物，及其在治疗慢性肾病、肾或心脏纤维化、糖尿病肾病、充血性心力衰竭、高血压、原发性醛固酮增多症和库欣综合征的药物中的用途，其中通式(I)中的各取代基与说明书中的定义相同。

  公开号：

  WO2024109885A1
• 作为产物：
  描述：

  4-溴-2-氟苯胺 在 potassium tert-butylate 、 sodium hydride 、 sodium hydroxide 作用下， 以 乙醇 、 氯仿 、 水 、 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 27.5h， 生成 7-溴-4-甲基-2H-苯并[B][1,4]噁嗪-3(4H)-酮
  参考文献：
  名称：

  Heteroatom insertion into 3,4-dihydro-1H-quinolin-2-ones leads to potent and selective inhibitors of human and rat aldosterone synthase

  摘要：

  Aldosterone synthase (CYP11B2) catalyzes the conversion of 11-deoxycorticosterone to aldosterone via corticosterone and 18-hydroxycorticosterone. CYP11B2 is regarded as a new target for several cardiovascular diseases which are associated with chronically elevated aldosterone levels such as hypertension, congestive heart failure and myocardial fibrosis. In this paper, we optimized heterocycle substituted 3,4-dihydropyridin-2(1H)-ones as CYP11B inhibitors by systematic introduction of heteroatoms and by bioisosteric exchange of the lactame moiety by a sultame moiety. The most promising compounds regarding inhibition of human CYP11B2 and selectivity versus human enzymes CYP11B1, CYP17, and CYP19 were tested for inhibition of rat CYP11B2. Thus, we discovered compounds 4 and 9 which show potent inhibition of hCYP11B2 (IC50 < 1 nM) and the corresponding rat enzyme (4: 64%, 9: 51% inhibition, at 2 mu M). (C) 2015 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2014.12.022

文献信息

• [EN] PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS<br/>[FR] DÉRIVÉS DE PYRIDINONE ET DE PYRIMIDINONE COMME INHIBITEURS DU FACTEUR XIA
  申请人：ONO PHARMACEUTICAL CO

  公开号：WO2013093484A1

  公开（公告）日：2013-06-27

  The present invention provides compounds of the general formula (I), their salts and N- oxides, and solvates and prodrugs thereof (wherein the characters are as defined in the description). The compounds of the general formula (I) are inhibitors of Factor XIa, so that they are useful in the prevention of and/or therapy for thromboembolic diseases.

  本发明提供了一般式(I)的化合物，它们的盐和N-氧化物，以及它们的溶剂合物和前药（其中字符如描述中所定义）。一般式(I)的化合物是因子XIa的抑制剂，因此它们在预防和/或治疗血栓栓塞疾病方面是有用的。
• SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS
  申请人：LUPIN LIMITED

  公开号：US20160145268A1

  公开（公告）日：2016-05-26

  The invention relates to compounds of Formula (I) and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine for the treatment of diseases, disorders associated with the modulation of calcium release-activated calcium (CRAC) channel. The invention also relates to pharmaceutical compositions containing such compounds in treating diseases disorders associated with calcium release-activated calcium (CRAC) channel modulators. wherein, ring D is Formula (a) or Formula (b): A and B, which may be same or different, are independently CR 3 or N; Y is CR 3 or N; L is selected from —NR 2 C(O)—, —C(O)NR 2 — and —NR 2 CR a R b —; R a and R b are independently hydrogen, halogen or substituted or unsubstituted alkyl; ring E is selected from the Formula (i) to (vii).

  该发明涉及式(I)的化合物及其药用可接受盐，其中取代基如本文所述，并且它们在医学上用于治疗与钙释放激活钙（CRAC）通道调节相关的疾病和紊乱。该发明还涉及含有这种化合物的药物组合物，用于治疗与钙释放激活钙（CRAC）通道调节剂相关的疾病和紊乱。其中，环D是式(a)或式(b)：A和B，可以相同也可以不同，分别独立地为CR3或N；Y为CR3或N；L选自—NR2C(O)—、—C(O)NR2—和—NR2CRaRb—；Ra和Rb独立地为氢、卤素或取代或未取代的烷基；环E选自式(i)至式(vii)。
• COMPOUNDS
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：US20150152112A1

  公开（公告）日：2015-06-04

  The present invention provides compounds of the general formula (I), their salts and N-oxides, and solvates and prodrugs thereof (wherein the characters are as defined in the description). The compounds of the general formula (I) are inhibitors of Factor XIa, so that they are useful in the prevention of and/or therapy for thromboembolic diseases.

  本发明提供了一般式（I）的化合物，它们的盐和N-氧化物，以及它们的溶剂化物和前药（其中字符如描述中所定义）。一般式（I）的化合物是因子XIa的抑制剂，因此它们在预防和/或治疗血栓性疾病方面非常有用。
• Pyrimidinone and its derivatives inhibiting factor XIa
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：US10717738B2

  公开（公告）日：2020-07-21

  The present invention provides compounds of the general formula (I), their salts and N-oxides, and solvates and prodrugs thereof (wherein the characters are as defined in the description). The compounds of the general formula (I) are inhibitors of Factor XIa, so that they are useful in the prevention of and/or therapy for thromboembolic diseases.

  本发明提供通式(I)化合物、其盐类和N-氧化物，以及其溶解物和原药（其中特征如描述中所定义）。通式（I）化合物是因子 XIa 的抑制剂，因此可用于预防和/或治疗血栓栓塞性疾病。
• Bicyclic imidazole derivatives useful for the treatment of renal diseases, cardiovascular diseases and fibrotic diseases
  申请人：Boehringer Ingelheim International GmbH

  公开号：US10858342B2

  公开（公告）日：2020-12-08

  The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5 and n are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

  本发明涉及式 I 的化合物：及其药学上可接受的盐类，其中 R1、R2、R3、R4、R5 和 n 如本文所定义。本发明还涉及包含这些化合物的药物组合物、使用这些化合物治疗各种疾病和失调的方法、制备这些化合物的工艺以及在这些工艺中有用的中间体。